OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

797 Projects | 548 Researchers | $376,488,329 Invested

2025

Emory University

Thomas Kukar, PhD

Development of a granulin biologic to treat progranulin deficient FTD.

  • Funding Amount: $349,890
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Proteostasis
  • Status: Active

2025

Circular Genomics Inc

Nikolaos Mellios, MD, PhD

Alzheimer’s disease specificity and sensitivity analyses of circRNA blood biomarkers

  • Funding Amount: $250,000
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2025

University of Gothenburg

Henrik Zetterberg, MD, PhD

Quality control (QC) program for CSF and plasma biomarkers for Alzheimer’s disease

  • Funding Amount: $1,999,997
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2025

Sunbird Bio

Mario Morken, MS/MBA

Proof-of-Principal clinical study for blood based extracellular vesicle bound biomarker signatures quantifying brain alpha synuclein aggregation state

  • Funding Amount: $249,887
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Target: Synuclein
  • Status: Active

2025

Banner Health

Nicholas Ashton, PhD

Determining %p-tau217 and MTBR-243 by immunoassay

  • Funding Amount: $250,000
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2024

MoCA Cognition

Ziad Nasreddine

Scientific validation of a digital MoCA for use in the general practice

  • Funding Amount: $1,036,093
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active

2024

Johns Hopkins University

Philip Wong, PhD

Develop a diagnostic biomarker for frontotemporal dementia.

  • Funding Amount: $640,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: TDP-43
  • Status: Active

2024

Alamar Biosciences

Xiao-Jun Ma, PhD

Development of ARGO DX™ for a new generation of blood-based diagnostics for Alzheimer’s disease and related neurodegenerative diseases

  • Funding Amount: $10,016,094
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active

2024

Polku Therapeutics

Timo Myöhänen, PhD

Novel prolyl oligopeptidase ligands to target Tau in frontotemporal dementia and other tauopathies

  • Funding Amount: $282,600
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Active

2024

Transposon Therapeutics

Andrew Satlin, MD

A Phase 2 Clinical Trial to Study the Effect of TPN-101, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with Alzheimer's Disease

  • Funding Amount: $4,995,519
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuronal Degeneration
  • Status: Active